Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05780307 | IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors | unknown | Phase 1 | 48 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT05883007 | Dose Optimized BNCT for Head and Neck Cancer(ST-BNCT2001) | unknown | Phase 1 | 30 | Southern Tohoku BNCT Research CenterOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05498389 | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | unknown | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT03797391 | A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 186 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | May 31, 2023 | clinicaltrials |
| NCT05393986 | Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | unknown | Phase 1 | 63 | Peking UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | May 31, 2023 | clinicaltrials |
| NCT05140811 | A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | unknown | Phase 1 / Phase 2 | 126 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05771883 | A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide | unknown | Phase 1 / Phase 2 | 102 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT04923048 | A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL. | unknown | Phase 1 / Phase 2 | 460 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 22, 2023 | clinicaltrials |
| NCT03982212 | A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors | unknown | Phase 1 | 10 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05471323 | Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML | unknown | Phase 1 | 36 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05858814 | RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT | unknown | Phase 1 / Phase 2 | 72 | Guangdong Ruishun Biotech Co., LtdINDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT04471064 | A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 60 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies(ANCHOR2) | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT05271682 | A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma | unknown | Phase 1 | 40 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05859373 | To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 78 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05607693 | A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects | unknown | Phase 1 | 52 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT05857982 | Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 20 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02632396 | Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission | unknown | Phase 1 / Phase 2 | 12 | Emory UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05843305 | A Study of BPI-452080 in Subjects With Solid Tumors | unknown | Phase 1 | 87 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT03217669 | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | unknown | Phase 1 | 15 | Chao HuangOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04356846 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05723432 | KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma | unknown | Phase 1 / Phase 2 | 84 | Shanghai Kanda Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 27, 2023 | clinicaltrials |
| NCT05833984 | Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas | unknown | Phase 1 / Phase 2 | 309 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03827070 | Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma(DPTA) | unknown | Phase 1 | 12 | Center Trials & Treatment EuropeNETWORK | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05749133 | Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | unknown | Phase 1 / Phase 2 | 18 | XuYanOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT04652440 | Ablation Combined With PD-1 in HCC: Phase II Study | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04265963 | CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 45 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04271410 | CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04271800 | Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04272125 | Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04272151 | Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04648475 | Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04649983 | CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04782193 | a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04861480 | Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 | 18 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03510767 | A Study of TQ-B3525 on Tolerance and Pharmacokinetics | unknown | Phase 1 | 60 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05438394 | Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM | unknown | Phase 1 | 24 | Peking University People's HospitalOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05363826 | Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac® | unknown | Phase 1 | 30 | Photolitec LLCINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT04363242 | A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions | unknown | Phase 1 | 22 | Synermore Biologics Co., Ltd.INDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05278364 | Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 184 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05308225 | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 72 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03743298 | Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma | unknown | Phase 1 | 20 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05641493 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation | unknown | Phase 1 / Phase 2 | 49 | Shanghai Henlius BiotechINDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05697510 | Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM(SILTUXILAM) | unknown | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05746728 | Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | unknown | Phase 1 / Phase 2 | 45 | Huihua XiongOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05503355 | A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML | unknown | Phase 1 / Phase 2 | 80 | BioSight Ltd.INDUSTRY | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05798455 | Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Tabriz University of Medical SciencesOTHER | 1 | Apr 4, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 7, 2023source: clinicaltrials